This content is machine translated Heart failure SGLT-2 inhibitors – great therapeutic potential in HFrEF patients. In addition to the SGLT-2 inhibitor dapagliflozin, which was also approved by Swissmedic last July for the treatment of heart failure (HFrEF) in non-diabetics, another member of this drug class,…
View Post 4 min This content is machine translated SGLT-2 inhibitors Dapagliflozin now also available for non-diabetics for the treatment of heart failure (HFrEF) Based on the results of the DAPA-HF study, Swissmedic has approved dapagliflozin for the treatment of heart failure with reduced ejection fraction (HFrEF), whether or not patients have type 2…
View Post 3 min This content is machine translated Chronic renal failure Dapagliflozin meets primary endpoints ahead of schedule The Phase III DAPA-CKD study will be terminated earlier than planned due to proven efficacy in patients with chronic renal failure. Dapagliflozin is the first SGLT2 inhibitor to show meaningful…
